As Japan Rebuke Of Diovan Grows, Novartis Tries To Overcome Scandal
This article was originally published in PharmAsia News
Executive Summary
Eight Japan hospitals have stopped prescribing the Novartis blood-pressure drug Diovan (valsartan) as the Swiss drug maker faces increasing resistance to its most popular drug in its second-largest market.